Tatsuhiro Matsuo Selected Research

psicose (D-psicose)

1/2017	Comparison of Anti-Obesity Effect between Two Types of Syrup Containing Rare Sugars in Wistar Rats.
11/2015	Rare sugar D-allulose: Potential role and therapeutic monitoring in maintaining obesity and type 2 diabetes mellitus.
3/2014	D-psicose increases energy expenditure and decreases body fat accumulation in rats fed a high-sucrose diet.
1/2013	Inhibition by dietary D-psicose of body fat accumulation in adult rats fed a high-sucrose diet.
3/2012	The 90-day oral toxicity of d-psicose in male Wistar rats.
11/2009	The study on long-term toxicity of d-psicose in rats.
9/2009	d-Psicose Inhibits Intestinal alpha-Glucosidase and Suppresses the Glycemic Response after Ingestion of Carbohydrates in Rats.
9/2006	Effects of dietary D-psicose on diurnal variation in plasma glucose and insulin concentrations of rats.
1/2003	Metabolic effects of D-psicose in rats: studies on faecal and urinary excretion and caecal fermentation.
12/2002	Effects of oral acute administration and subchronic feeding of several levels of D-psicose in rats.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tatsuhiro Matsuo Research Topics

Disease

9	Body Weight (Weight, Body) 01/2017 - 02/2002
8	Obesity 08/2022 - 01/2013
4	Insulin Resistance 02/2019 - 01/2012
4	Weight Gain 01/2017 - 12/2003
4	Hyperglycemia 11/2015 - 09/2006
4	Hypertrophy 03/2012 - 12/2002
2	Hypertriglyceridemia 02/2019 - 01/2017
2	Diarrhea 01/2018 - 01/2013
2	Type 2 Diabetes Mellitus (MODY) 11/2015 - 01/2013
2	Hypertension (High Blood Pressure) 11/2015 - 01/2013
2	Diabetes Mellitus 04/2015 - 01/2013
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/2019
1	Hypersensitivity (Allergy) 01/2017
1	Glucose Intolerance 11/2015
1	Dyslipidemias (Dyslipidemia) 11/2015
1	Atherosclerosis 11/2015
1	Frailty 04/2015
1	Fatty Liver 01/2014
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2013
1	Osteoporosis 12/2003
1	Metabolic Bone Diseases (Osteopenia) 12/2003
1	Iron Deficiencies 08/2003
1	Iron-Deficiency Anemia (Anemia, Iron Deficiency) 12/2002
1	Anemia 04/2002
1	Weight Loss (Weight Reduction) 02/2002

Drug/Important Bio-Agent (IBA)

11	psicose (D-psicose)IBA 01/2017 - 02/2002
7	Sucrose (Saccharose)IBA 01/2017 - 02/2002
4	SugarsIBA 08/2022 - 02/2002
4	Proteins (Proteins, Gene)FDA Link 01/2017 - 12/2003
3	LipidsIBA 02/2019 - 01/2013
2	Sweetening Agents (Sweeteners)IBA 01/2017 - 02/2002
2	Insulin (Novolin)FDA Link 11/2015 - 01/2013
2	FructoseIBA 09/2006 - 02/2002
1	Glucose (Dextrose)FDA LinkGeneric 02/2019
1	FlavonesIBA 02/2019
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 02/2019
1	LigandsIBA 02/2019
1	AdiponectinIBA 02/2019
1	Ethanol (Ethyl Alcohol)IBA 02/2019
1	Arabinose (L-Arabinose)IBA 01/2018
1	MonosaccharidesIBA 01/2017
1	ThiazolidinedionesIBA 11/2015
1	Metformin (Glucophage)FDA LinkGeneric 11/2015
1	Dietary ProteinsIBA 04/2015
1	Triglycerides (Triacylglycerol)IBA 06/2014
1	EnzymesIBA 03/2014
1	Ligases (Synthetase)IBA 01/2014
1	AcidsIBA 01/2014
1	Biomarkers (Surrogate Marker)IBA 01/2014
1	Starch (Cornstarch)IBA 06/2013
1	High Fructose Corn SyrupIBA 06/2013
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2013
1	Trans Fatty AcidsIBA 01/2013
1	Stearoyl-CoA DesaturaseIBA 01/2012
1	MaltoseIBA 09/2009
1	GlucocorticoidsIBA 12/2003
1	ZincIBA 08/2003
1	Volatile Fatty AcidsIBA 01/2003
1	IronIBA 04/2002

Therapy/Procedure

3	Therapeutics 12/2003 - 04/2002
1	Traditional Medicine (Folk Remedies) 02/2019
1	Caloric Restriction 11/2015
1	Glycemic Control 11/2015
1	Injections 12/2003